Advances in the management of glioblastoma: the role of temozolomide and MGMT testing

Reena P Thomas, Lawrence Recht, Seema NagpalDepartment of Neurological Sciences, Stanford University Hospital, Stanford, CA, USAAbstract: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas RP, Recht L, Nagpal S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9b57b4faeae04177967a9e17ae0e410b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b57b4faeae04177967a9e17ae0e410b
record_format	dspace
spelling	oai:doaj.org-article:9b57b4faeae04177967a9e17ae0e410b2021-12-02T01:11:17ZAdvances in the management of glioblastoma: the role of temozolomide and MGMT testing1179-1438https://doaj.org/article/9b57b4faeae04177967a9e17ae0e410b2012-12-01T00:00:00Zhttp://www.dovepress.com/advances-in-the-management-of-glioblastoma-the-role-of-temozolomide-an-a11815https://doaj.org/toc/1179-1438Reena P Thomas, Lawrence Recht, Seema NagpalDepartment of Neurological Sciences, Stanford University Hospital, Stanford, CA, USAAbstract: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics &ndash; particularly the use of O6-methylguanine-DNA methyltransferase status &ndash; affect clinical management.Keywords: glioblastoma, temozolomide, PredictMDx&trade;, MGMTThomas RPRecht LNagpal SDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss default, Pp 1-9 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Thomas RP Recht L Nagpal S Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
description	Reena P Thomas, Lawrence Recht, Seema NagpalDepartment of Neurological Sciences, Stanford University Hospital, Stanford, CA, USAAbstract: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics &ndash; particularly the use of O6-methylguanine-DNA methyltransferase status &ndash; affect clinical management.Keywords: glioblastoma, temozolomide, PredictMDx&trade;, MGMT
format	article
author	Thomas RP Recht L Nagpal S
author_facet	Thomas RP Recht L Nagpal S
author_sort	Thomas RP
title	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
title_short	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
title_full	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
title_fullStr	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
title_full_unstemmed	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
title_sort	advances in the management of glioblastoma: the role of temozolomide and mgmt testing
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/9b57b4faeae04177967a9e17ae0e410b
work_keys_str_mv	AT thomasrp advancesinthemanagementofglioblastomatheroleoftemozolomideandmgmttesting AT rechtl advancesinthemanagementofglioblastomatheroleoftemozolomideandmgmttesting AT nagpals advancesinthemanagementofglioblastomatheroleoftemozolomideandmgmttesting
_version_	1718403274186424320

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing

Ejemplares similares